Please wait while the transcript is being prepared...
0:00
Hello, everyone!
My name is Alex Sverdlov,
I'm a Senior Director of
Biostatistics at Novartis.
Today, I'm going to give
a brief introduction to
the field of digital
therapeutics.
0:16
Here is the outline of my talk.
I'll start with an overview of
digital health technologies and
their importance in
modern healthcare.
I will go over some
defining features of
digital therapeutics and
provide some examples.
Then, I will speak to
the importance and
the need for building
the evidence base for
digital therapeutics,
and the potential added value of
these products in practice.
Finally, I will
give a summary and
the future perspective
on digital therapeutics.
0:51
The idea of using technology to
provide life support and
treatment is not new.
Medical device systems of
various complexity have
become ubiquitous.
One can give
multiple examples of
medical devices in
different areas.
For instance,
the cardiac pacemaker is
a remarkable invention with
about a 300-year history,
that has been a
critical driver of
many developments in cardiac
science and medicine.
Its development started with
the experiments in
electrophysiology in
the 18th century.
With the creation of initial
machines in the 1920s and
external stimulators designed
and built in the 1950s.
It was miniaturized
and transitioned to
microprocessor-controlled
implantable pacemakers in the 1990s,
and it continued development
in the early 21st century.
As another example,
let us consider the
success stories of
various artificial organs
such as artificial kidneys.
Hemodialysis as a means of
replacing renal function,
started in the 20th century and
these tools evolved from
capillary dialyzers and sorbent
systems in the 1960s to
wearable artificial
kidney systems.
A recent U.S. FDA clearance of
the Artificial Kidney 98
Dialysis Machine highlights
a significant milestone in
bringing new improved
quality of care for
many patients who
are on hemodialysis.
